These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26967022)

  • 1. Advantages and disadvantages of discrete-event simulation for health economic analyses.
    Caro JJ; Möller J
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):327-9. PubMed ID: 26967022
    [No Abstract]   [Full Text] [Related]  

  • 2. [Discrete-event simulation models in the economic evaluation of health technologies and health products].
    Rodríguez Barrios JM; Serrano D; Monleón T; Caro J
    Gac Sanit; 2008; 22(2):151-61. PubMed ID: 18420015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder.
    Vataire AL; Aballéa S; Antonanzas F; Roijen LH; Lam RW; McCrone P; Persson U; Toumi M
    Value Health; 2014 Mar; 17(2):183-95. PubMed ID: 24636376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic data transferability for HTA: are we there yet?
    Manca A
    Value Health; 2009 Jun; 12(4):407. PubMed ID: 19900247
    [No Abstract]   [Full Text] [Related]  

  • 5. Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.
    Frederix GW; Haji Ali Afzali H; Dasbach EJ; Ward RL
    Pharmacoeconomics; 2015 Aug; 33(8):777-81. PubMed ID: 25827099
    [No Abstract]   [Full Text] [Related]  

  • 6. Resource modelling: the missing piece of the HTA jigsaw?
    Thokala P; Dixon S; Jahn B
    Pharmacoeconomics; 2015 Mar; 33(3):193-203. PubMed ID: 25411095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer.
    Degeling K; Schivo S; Mehra N; Koffijberg H; Langerak R; de Bono JS; IJzerman MJ
    Value Health; 2017 Dec; 20(10):1411-1419. PubMed ID: 29241901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technology assessment in Europe.
    Kristensen FB
    Scand J Public Health; 2009 Jun; 37(4):335-9. PubMed ID: 19493989
    [No Abstract]   [Full Text] [Related]  

  • 9. Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.
    Wu EQ; Zhou ZY; Xie J; Metallo C; Thokala P
    Pharmacoeconomics; 2019 Nov; 37(11):1349-1354. PubMed ID: 31591672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Health economics and HTA].
    Kulp W; Greiner W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):257-63. PubMed ID: 16465516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling Treatment Sequences in Pharmacoeconomic Models.
    Zheng Y; Pan F; Sorensen S
    Pharmacoeconomics; 2017 Jan; 35(1):15-24. PubMed ID: 27722894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model Structuring for Economic Evaluations of New Health Technologies.
    Haji Ali Afzali H; Bojke L; Karnon J
    Pharmacoeconomics; 2018 Nov; 36(11):1309-1319. PubMed ID: 30030816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence-based decision-making 3: Health technology assessment.
    O'Reilly D; Campbell K; Vanstone M; Bowen JM; Schwartz L; Assasi N; Goeree R
    Methods Mol Biol; 2015; 1281():417-41. PubMed ID: 25694325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches for economic evaluations of health care technologies.
    Tarride JE; Blackhouse G; Bischof M; McCarron EC; Lim M; Ferrusi IL; Xie F; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):307-16. PubMed ID: 19394571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines for reporting health economic evaluation studies.
    Silva END; Silva MT; Augustovski F; Husereau D; Pereira MG
    Epidemiol Serv Saude; 2017; 26(4):895-898. PubMed ID: 29211152
    [No Abstract]   [Full Text] [Related]  

  • 16. A View from the Bridge: Health Economic Evaluation - A Value-Based Framework?
    Briggs A
    Health Econ; 2016 Dec; 25(12):1499-1502. PubMed ID: 27870333
    [No Abstract]   [Full Text] [Related]  

  • 17. Economic evaluation guidelines in Latin America: a current snapshot.
    Augustovski F; Garay OU; Pichon-Riviere A; Rubinstein A; Caporale JE
    Expert Rev Pharmacoecon Outcomes Res; 2010 Oct; 10(5):525-37. PubMed ID: 20950069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation in medical information technology: why the numbers don't add up.
    Eisenstein EL; Ortiz M; Anstrom KJ; Crosslin DR; Lobach DF
    AMIA Annu Symp Proc; 2006; 2006():914. PubMed ID: 17238533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ICER is good for us--Possibly not for you, he or she.
    Pekurinen M
    Int J Technol Assess Health Care; 2011 Jan; 27(1):98. PubMed ID: 21262090
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the expected rewards between probabilistic and deterministic analyses in a Markov model.
    Xie X; Yeung MW; Wang Z; Wang M; Gajic-Veljanoski O; Ng V; Volodin A
    Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):169-175. PubMed ID: 31116609
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.